Sage Journals: Discover world-class research

Abstract

Objective:

To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing–remitting multiple sclerosis (RRMS).

Methods:

A longitudinal study based on two previously described cohorts of IFNβ-treated RRMS patients was conducted. Patients were classified according to clinical activity after 2 years (clinical cohort) or to clinical and radiological activity after 1 year (magnetic resonance imaging (MRI) cohort). Multivariate Cox models were calculated for early disease activity predicting long-term disability.

Results:

A total of 516 patients from two different cohorts were included in the analyses. Persistent clinical disease activity during the first 2 years of therapy predicted severe long-term disability (clinical cohort). In the MRI cohort, modified Rio score and no or minimal evidence of disease activity (NEDA/MEDA) did not identify patients with risk of Expanded Disability Status Scale (EDSS) worsening. However, a Rio score ≥ 2 (hazard ratio (HR): 3.3, 95% confidence interval (CI): 1.7–6.4); ≥3 new T2 lesions (HR: 2.9, 95% CI: 1.5–5.6); or ≥2 Gd-enhancing lesions (HR: 2.1, 95% CI: 1.1–4) were able to identify patients with EDSS worsening.

Conclusion:

Although early activity during IFNβ therapy is associated with poor long-term outcomes, minimal degree of activity does not seem to be predictive of EDSS worsening over 6.7-year mean follow-up.

Keywords

Multiple sclerosis disability interferon-beta treatment response MRI outcome measurement

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

Jacobs

Cookfair

Rudick

et al . Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–294.

PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

Paty

: The University of British Columbia MS/MRI Study Group and The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–667.

Simon

Jacobs

Campion

et al et al .: The Multiple Sclerosis Collaborative Research Group. Magnetic Resonance studies of intramuscular interferon β-1a for the relapsing multiple sclerosis. Ann Neurol 1998; 43: 79–87.

Paty

DW.

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197–206.

Concato

Shah

Horwitz

RI.

Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000; 342: 1887–1892.

Río

Comabella

Montalban

Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553–560.

Rudick

Polman

CH.

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009; 8: 545–559.

10.

Rudick

Lee

Simon

et al . Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548–555.

11.

Prosperini

Gallo

Petsas

et al . One-year MRI scans predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16: 1202–1209.

12.

Rio

Castillo

Rovira

et al . Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848–853.

13.

Sormani

Rio

Tintore

et al . Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605–612.

14.

Prosperini

Mancinelli

De Giglio

et al . Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler 2014; 20: 566–576.

15.

Bermel

You

Foulds

et al . Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 73: 95–103.

16.

Uher

Vaneckova

Sobisek

et al . Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Mult Scler 2017; 23: 51–61.

17.

Rio

Nos

Tintoré

et al . Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344–352.

18.

Rotstein

Healy

Malik

et al . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.

19.

Grand’Maison

Bhan

Freedman

et al . Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care. Can J Neurol Sci 2013; 40: 527–535.

20.

Sormani

Gasperini

Romeo

et al . Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology 2016; 87(2): 134–140.

21.

Kremenchutzky

Cottrell

Rice

et al . The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain 1999; 122: 1941–1950.

22.

Molyneux

Miller

Filippi

et al . Visual analysis of serial T2-weighted MRI in multiple sclerosis: Intra and interobserver reproducibility. Neuroradiology 1999; 41: 882–888.

23.

Goodin

Reder

Ebers

et al . Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNB-1b trial. Neurology 2012; 78: 1315–1322.

24.

Bermel

Weinstock-Guttman

Bourdette

et al . Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study. Mult Scler 2010; 16: 588–596.

25.

Trojano

Pellegrini

Fuiani

et al . New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300–306.

26.

Goodin

Traboulsee

Knappertz

et al . Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 282–287.

27.

Río

Rovira

Tintoré

et al . Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler 2008; 14: 479–484.

28.

Dobson

Rudick

Turner

et al . Assessing treatment response to interferon-β: Is there a role for MRI? Neurology 2014; 82: 248–254.

29.

Sormani

De Stefano

Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol 2013; 9: 504–512.

30.

Romeo

Martinelli

Rodegher

et al . Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients. Eur J Neurol 2015; 22: 973–980.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB

Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients

Abstract

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material